deltatrials
Recruiting PHASE2 INTERVENTIONAL 4-arm NCT03339128

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Sponsor: AbbVie

Conditions Irritable Bowel Syndrome
Interventions Eluxadoline Placebo
Updated 36 times since 2017 Last updated: Sep 17, 2025 Started: Nov 15, 2017 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03339128, this PHASE2 trial focuses on Irritable Bowel Syndrome and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 36 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~May 2020 · 11 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Nov 2021 · 9 months · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 8 months · monthly snapshot

Change History

36 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  5. May 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

▶ Show 31 earlier versions

  1. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Oct 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  6. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  7. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  8. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  9. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  10. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  11. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  12. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  13. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  14. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  15. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  16. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  17. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  18. Nov 2021 — May 2022 [monthly]

    Recruiting PHASE2

  19. Feb 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  20. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  21. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  22. Jul 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  23. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  24. Jun 2019 — May 2020 [monthly]

    Recruiting PHASE2

  25. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  26. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  27. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  28. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  29. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  30. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  31. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Atlanta, United States , Blackpool, United Kingdom , Budapest, Hungary , Corona, United States , Edmonton, Canada , Fort Worth, United States , Garden Grove, United States , Gdansk, Poland , Hot Springs, United States and 31 more locations